A medication commonly used to treat type 2 diabetes and aid in weight loss may have an unexpected benefit: the potential to repair damage caused by osteoarthritis. Recent research suggests the active ingredient semaglutide could protect and even restore tissues affected by the condition, the most prevalent form of arthritis worldwide.
The research, conducted by teams from China and the United States and published in the scientific journal Cell Metabolism, indicates the drug may directly influence the metabolism of cartilage cells, rather than simply reducing stress on joints through weight loss.
Beyond Weight Loss: A New Mechanism of Action
Semaglutide is the active substance in medications Ozempic and Wegovy. These drugs mimic the action of a natural hormone called GLP-1 (glucagon-like peptide‑1), which stimulates insulin release and helps regulate blood sugar. Simultaneously, the hormone signals the brain to promote feelings of fullness, leading to reduced appetite.
Previously, the benefits of these medications for joints were thought to stem primarily from indirect effects – weight loss. Lower body weight translates to less pressure on joints, particularly the knees and hips. This discovery is significant as it suggests a potential treatment option for a condition affecting millions, even independent of weight management.
However, the new research suggests semaglutide may have a more profound effect, acting directly on the cells responsible for producing and maintaining healthy cartilage.
“This study highlights the potential of semaglutide as a treatment for metabolic osteoarthritis and shows that there is a repair mechanism independent of weight loss,” the authors noted, according to Science Alert.
Promising Results in Both Animal and Human Studies
In experiments conducted on mice, researchers observed that semaglutide altered how cartilage cells, called chondrocytes, function. Essentially, the drug “reprograms” their metabolism, allowing them to produce more energy and better survive the conditions created by osteoarthritis.
To determine if these effects observed in animals could translate to humans, researchers also conducted a tiny clinical study. Twenty participants, aged 50 to 75, who were both obese and suffering from osteoarthritis were randomly divided into two groups.
One group received treatment with sodium hyaluronate – a form of hyaluronic acid used to lubricate joints. The other group received the same therapy, but in combination with semaglutide.
After 24 weeks, patients who received semaglutide reported lower pain scores and significant improvements in knee function. MRI scans revealed thicker cartilage and signs of regeneration in weight-bearing areas of the joint.
The discovery adds to a growing body of research suggesting that GLP-1 based medications may have medical benefits extending beyond weight control and blood sugar management.
However, researchers caution that the results should be interpreted with prudence. Animal studies do not always translate into long-term benefits for humans and semaglutide itself has potential side effects and limitations.
Osteoarthritis is the most common form of arthritis, affecting approximately 600 million people globally. Experts estimate that by 2050, the number of affected individuals could reach one billion.
The disease is becoming increasingly prevalent among the active and relatively young population, potentially leading to decades of pain and functional limitations.
Currently, most available treatments are primarily palliative, meaning they reduce pain and inflammation but do not stop or reverse cartilage degradation.
